Monitor the company's periodic filings (10-Q/10-K) for disclosure of actual shares sold under the ATM program and the use of proceeds. The conflict of interest with a director serving as a managing director at Wainwright warrants attention to related-party transaction disclosures.
Price Chart
Executive Summary
Niki BioSolutions, Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets to sell up to $1,396,000 of its common stock through an at-the-market offering program. The filing follows a 424B5 prospectus supplement filed the same day and a recently effective S-3 shelf registration statement, indicating the company is actively raising capital. The ATM facility provides flexible financing but creates potential dilution for existing shareholders.
Key Financial Metrics
Key Facts
- Niki BioSolutions entered into an ATM offering agreement with H.C. Wainwright and Brookline Capital Markets on October 9, 2026.
- The company may sell up to $1,396,000 of common stock through the ATM facility.
- Wainwright will receive a 3.0% placement fee on gross proceeds from sales.
- The company's largest shareholder and a director, Dr. Kira Sheinerman, is a managing director of Wainwright, creating a FINRA Rule 5121 conflict of interest.
- Brookline Capital Markets is acting as a qualified independent underwriter for no additional compensation.
- The ATM offering is being made under a shelf registration statement (File No. 333-298608) declared effective on October 9, 2026.
- The last reported sale price of NIKI common stock on October 8, 2026 was $4.23 per share.
- The company has a public float of approximately $10.2 million as of October 8, 2026.
Financial Impact
Up to $1,396,000 in common stock may be sold, representing potential dilution of approximately 13% based on 2,938,625 shares outstanding and a $4.23 stock price.
Risk Factors
- Potential dilution to existing shareholders as shares are sold into the market.
- Conflict of interest due to director's affiliation with the selling agent.
- Historical underperformance of the stock following prior filings suggests limited positive catalyst potential.
- The company's small public float and limited market cap may amplify price pressure from ATM sales.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-108572 |
| Document: ea0308263-8k_nikibio.htm | 0001213900-26-108572 |
| Document: ea030826301ex5-1.htm | 0001213900-26-108572 |
| Document: 0001213900-26-108572-index-headers.html | 0001213900-26-108572 |
| Document: 0001213900-26-108572-index.html | 0001213900-26-108572 |
| Document: 0001213900-26-108572.txt | 0001213900-26-108572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 17d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 17d ago | 424B5 | — | awaiting T+1 | — | — |
Jul 20, 2026 14w ago | 8-K | $8.83 $9.54 | ▲ +8.04% | ▲ +7.21% | — |
Jul 16, 2026 14w ago | Press Release | $0.6924 $0.7000 | ▲ +1.10% | ▲ +2.09% | — |
Jun 10, 2026 19w ago | 6-K | $0.9038 $0.8900 | ▼ −1.53% | ▼ −3.23% | — |
Jun 4, 2026 20w ago | EFFECT | $1.09 $1.01 | ▼ −7.34% | ▼ −4.74% | — |
May 14, 2026 23w ago | 6-K | $0.8230 $0.8570 | ▼ −4.13% | ▼ −4.19% | — |
Mar 27, 2026 30w ago | 20-F | $0.8380 $0.7960 | ▲ +5.01% | ▲ +7.90% | — |
Mar 6, 2026 33w ago | Press Release | $0.8000 $0.7930 | ▲ +0.88% | ▲ +0.69% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers